Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACLX Arcellx	$70.25 +0.5%	$69.02	$47.86 ▼ $107.37	$3.90B	0.28	660,667 shs	2.29 million shs
LNTH Lantheus	$55.50 -2.4%	$70.16	$47.25 ▼ $118.21	$3.77B	0.14	1.21 million shs	1.06 million shs
PRAX Praxis Precision Medicines	$45.99 -2.0%	$49.05	$26.70 ▼ $91.83	$968.09M	2.62	447,647 shs	186,945 shs
PTCT PTC Therapeutics	$49.79 +0.0%	$48.77	$30.41 ▼ $58.38	$3.96B	0.54	1.08 million shs	650,687 shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACLX Arcellx	0.00%	-2.25%	-0.98%	+9.77%	-2.20%
LNTH Lantheus	+2.12%	+1.25%	-21.50%	-24.74%	-47.92%
PRAX Praxis Precision Medicines	-2.05%	+3.69%	-15.69%	+22.03%	-12.33%
PTCT PTC Therapeutics	+0.65%	+1.90%	+12.23%	+1.82%	+40.94%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACLX Arcellx	2.1227 of 5 stars	3.6	0.0	0.0	3.6	2.5	0.0
LNTH Lantheus	4.7624 of 5 stars	4.4	1.0	4.2	3.2	2.5	1.9
PRAX Praxis Precision Medicines	1.7013 of 5 stars	3.4	1.0	0.0	2.7	1.7	0.0
PTCT PTC Therapeutics	4.3263 of 5 stars	4.3	1.0	4.4	2.2	0.8	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACLX Arcellx	3.13	Buy	$114.31	62.72% Upside
LNTH Lantheus	2.71	Moderate Buy	$105.50	90.09% Upside
PRAX Praxis Precision Medicines	2.75	Moderate Buy	$85.88	86.73% Upside
PTCT PTC Therapeutics	2.63	Moderate Buy	$69.15	38.89% Upside

Current Analyst Ratings Breakdown

Latest PRAX, PTCT, LNTH, and ACLX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/20/2025	PTCT PTC Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$79.00 ➝ $73.00
8/20/2025	PTCT PTC Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$76.00 ➝ $71.00
8/20/2025	PTCT PTC Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$82.00 ➝ $76.00
8/11/2025	LNTH Lantheus	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Hold	$111.00 ➝ $63.00
8/8/2025	PTCT PTC Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$70.00
8/8/2025	PTCT PTC Therapeutics	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
8/8/2025	PTCT PTC Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$60.00 ➝ $63.00
8/8/2025	PTCT PTC Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$78.00 ➝ $79.00
8/7/2025	LNTH Lantheus	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$112.00 ➝ $73.00
8/7/2025	LNTH Lantheus	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$120.00 ➝ $70.00
8/5/2025	PRAX Praxis Precision Medicines	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$105.00 ➝ $115.00

(Data available from 8/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACLX Arcellx	$107.94M	36.09	N/A	N/A	$7.07 per share	9.94
LNTH Lantheus	$1.52B	2.48	$7.07 per share	7.85	$17.16 per share	3.23
PRAX Praxis Precision Medicines	$8.55M	113.23	N/A	N/A	$19.21 per share	2.39
PTCT PTC Therapeutics	$1.76B	2.24	N/A	N/A	($2.60) per share	-19.15

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACLX Arcellx	-$107.35M	-$3.42	N/A	N/A	N/A	-329.93%	-43.04%	-27.41%	11/6/2025 (Estimated)
LNTH Lantheus	$312.44M	$3.76	14.76	8.80	N/A	17.82%	34.06%	19.10%	11/5/2025 (Estimated)
PRAX Praxis Precision Medicines	-$182.82M	-$12.29	N/A	N/A	N/A	-2,137.48%	-60.07%	-54.84%	11/5/2025 (Estimated)
PTCT PTC Therapeutics	-$363.30M	$6.97	7.14	N/A	N/A	35.65%	-106.31%	30.61%	11/6/2025 (Estimated)

Latest PRAX, PTCT, LNTH, and ACLX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	ACLX Arcellx	-$1.03	-$0.94	+$0.09	-$0.94	$16.76 million	$7.55 million
8/7/2025	Q2 2025	PTCT PTC Therapeutics	-$1.07	-$0.83	+$0.24	-$0.83	$173.01 million	$178.88 million
8/6/2025	Q2 2025	LNTH Lantheus	$1.65	$1.57	-$0.08	$1.12	$389.69 million	$378.05 million
8/4/2025	Q2 2025 & Study Result	PRAX Praxis Precision Medicines	-$3.40	-$3.31	+$0.09	-$3.31	$0.15 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACLX Arcellx	N/A	N/A	N/A	N/A	N/A
LNTH Lantheus	N/A	N/A	N/A	N/A	N/A
PRAX Praxis Precision Medicines	N/A	N/A	N/A	N/A	N/A
PTCT PTC Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACLX Arcellx	N/A	3.81	3.81
LNTH Lantheus	0.49	4.29	4.07
PRAX Praxis Precision Medicines	N/A	6.31	6.31
PTCT PTC Therapeutics	N/A	3.62	3.57

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACLX Arcellx	96.03%
LNTH Lantheus	99.06%
PRAX Praxis Precision Medicines	67.84%
PTCT PTC Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
ACLX Arcellx	8.35%
LNTH Lantheus	1.50%
PRAX Praxis Precision Medicines	2.70%
PTCT PTC Therapeutics	5.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACLX Arcellx	80	55.46 million	50.83 million	Optionable
LNTH Lantheus	700	67.99 million	66.97 million	Optionable
PRAX Praxis Precision Medicines	110	21.05 million	20.48 million	Optionable
PTCT PTC Therapeutics	1,410	79.44 million	75.07 million	Optionable

PRAX, PTCT, LNTH, and ACLX Headlines

Recent News About These Companies

T. Rowe Price Investment Management Inc. Purchases New Holdings in PTC Therapeutics, Inc. $PTCT

August 27 at 4:49 AM | marketbeat.com

PTC Therapeutics participates in a conference call with Truist

August 25 at 12:49 AM | msn.com

Invesco Ltd. Boosts Holdings in PTC Therapeutics, Inc. $PTCT

August 25 at 3:30 AM | marketbeat.com

Cantor Fitzgerald Has Weak Outlook for PTCT FY2026 Earnings

August 24, 2025 | marketbeat.com

William Blair Cuts Earnings Estimates for PTC Therapeutics

August 23, 2025 | marketbeat.com

Cantor Fitzgerald Brokers Reduce Earnings Estimates for PTCT

August 23, 2025 | americanbankingnews.com

Bank of America Lowers PTC Therapeutics (NASDAQ:PTCT) Price Target to $76.00

August 22, 2025 | marketbeat.com

Wellington Management Group LLP Has $276.16 Million Holdings in PTC Therapeutics, Inc. $PTCT

August 22, 2025 | marketbeat.com

William Blair Lowers Earnings Estimates for PTC Therapeutics

August 22, 2025 | americanbankingnews.com

Bank of America Issues Pessimistic Forecast for PTC Therapeutics (NASDAQ:PTCT) Stock Price

August 22, 2025 | americanbankingnews.com

PTC Therapeutics (NASDAQ:PTCT) Stock Price Up 7.6% - Here's What Happened

August 21, 2025 | marketbeat.com

PTC Therapeutics price target lowered to $73 from $79 at Wells Fargo

August 21, 2025 | msn.com

JPMorgan adds PTC Therapeutics to Analyst Focus List after selloff

August 21, 2025 | msn.com

PTC Therapeutics to Participate at Upcoming Investor Conferences

August 21, 2025 | prnewswire.com

PTC Therapeutics (NASDAQ:PTCT) Price Target Cut to $71.00 by Analysts at Morgan Stanley

August 21, 2025 | americanbankingnews.com

Wells Fargo & Company Cuts PTC Therapeutics (NASDAQ:PTCT) Price Target to $73.00

August 21, 2025 | americanbankingnews.com

PTC Therapeutics price target lowered to $71 from $76 at Morgan Stanley

August 20, 2025 | msn.com

PTC Therapeutics price target lowered to $76 from $82 at BofA

August 20, 2025 | msn.com

Charles Schwab Investment Management Inc. Cuts Stock Position in PTC Therapeutics, Inc. $PTCT

August 20, 2025 | marketbeat.com

PTC Therapeutics, Inc. $PTCT Shares Sold by US Bancorp DE

August 20, 2025 | marketbeat.com

PTC Therapeutics Stock In The Spotlight After FDA Refuses Approval For Drug To Treat Neurodegenerative Disease, Analysts Are Divided

August 20, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRAX, PTCT, LNTH, and ACLX Company Descriptions

Arcellx NASDAQ:ACLX

$70.25 +0.35 (+0.50%)

Closing price 04:00 PM Eastern

Extended Trading

$70.16 -0.09 (-0.14%)

As of 04:54 PM Eastern

Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Lantheus NASDAQ:LNTH

$55.50 -1.34 (-2.36%)

Closing price 04:00 PM Eastern

Extended Trading

$55.48 -0.02 (-0.03%)

As of 04:20 PM Eastern

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Praxis Precision Medicines NASDAQ:PRAX

$45.99 -0.93 (-1.98%)

Closing price 04:00 PM Eastern

Extended Trading

$46.02 +0.02 (+0.05%)

As of 05:36 PM Eastern

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.

PTC Therapeutics NASDAQ:PTCT

$49.79 +0.01 (+0.02%)

Closing price 04:00 PM Eastern

Extended Trading

$49.77 -0.02 (-0.04%)

As of 04:20 PM Eastern

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time